NCT05054478View on ClinicalTrials.gov

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

February 29, 2028

Conditions

Plasma Cell Leukemia

Interventions

DRUG

Daratumumab

Daratumumab added to induction, first consolidation and second consolidation

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER